Meet The Professors: Pancreatic Cancer Edition, 2016 - Video 12Ongoing investigation of nal-IRI-containing regimens for patients with untreated mPAC
1:36 minutes.
TRANSCRIPTION:
DR GLYNN: Do you substitute the nanoliposomal irinotecan in for FOLFIRINOX now? And is it available to get it covered? DR LOVE: You mean as part of a triplet? DR GLYNN: Yes. DR BEKAII-SAAB: So these studies are undergoing to look actually at the triplet with MM-38, so nanoliposomal irinotecan/oxaliplatin plus 5-FU. So there is no safety data yet. So I wouldn’t use it before we actually have some of these results. The question, though, whether you really need in FOLFIRINOX to substitute irinotecan with nal-IRI is, again, unclear. So I wouldn’t really change practice at this point of time with the FOLFIRINOX regimen. DR LOVE: What do you think in terms of where that — I don't know what you would call it, FOL-nil or ox or something, but substituting nal-IRI for 5-FU in FOLFIRINOX? What do you think about the trials looking at it, and any other novel trial ideas being looked at with this drug? DR TEMPERO: Actually maybe Tony knows for sure, but I believe the trial is comparing against gemcitabine and nab paclitaxel, correct? DR BEKAII-SAAB: Nab paclitaxel. And there’s a third arm with 5-FU and nal-IRI. So the question is, gemcitabine/nab paclitaxel, 5-FU/nal-IRI. Then the third arm is 5-FU/nal-IRI plus oxaliplatin. DR TEMPERO: Right. So I think the way the trial is being done is the right way, because it will show whether this is a more convenient way of giving a difficult regimen. We’ll see. |